Focal Interest
Focal Interest

PARP inhibition in cancer therapy

External reference: https://openalex.org/T11914

  1. Talazoparib resistance in triple-negative breast cancer linked to BRN2 and SHLD2
    Study identifies BRN2-mediated and SHLD2-related resistance to talazoparib in BRCA-mutant breast cancer, proposing combination therapy approaches to improve neoadjuvant treatment outcomes.
  2. CTF18-RFC structure reveals how it binds PCNA
    Cryo-EM structure of human CTF18–RFC clamp loader bound to PCNA reveals autoinhibited conformation and unique structural features governing leading strand synthesis.